Financial Performance - Progyny reported revenue of $318.4 million for the quarter ended December 2025, reflecting a 6.7% increase year-over-year [1] - Earnings per share (EPS) for the quarter was $0.48, up from $0.42 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $303.93 million by 4.76% [1] - The company delivered an EPS surprise of 25.49%, with the consensus EPS estimate being $0.38 [1] Key Metrics - Utilization for female-only services was 0.5%, matching the two-analyst average estimate [4] - Average members reached 6,707, surpassing the two-analyst average estimate of 6,586 [4] - Revenue from pharmacy benefit services was $109.8 million, slightly below the estimated $110.78 million, representing a year-over-year decrease of 1.1% [4] - Revenue from fertility benefit services was $208.6 million, exceeding the three-analyst average estimate of $192.06 million, with a year-over-year increase of 11.3% [4] Stock Performance - Progyny's shares have returned -13.1% over the past month, while the Zacks S&P 500 composite has increased by 0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health an ...

Wall Street analysts expect Progyny (PGNY) to post quarterly earnings of $0.38 per share in its upcoming report, which indicates a year-over-year decline of 9.5%. Revenues are expected to be $303.93 million, up 1.8% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company announces its earnings, it is essentia ...

Core Insights - CVS Health reported a decline in fourth-quarter profit but exceeded Wall Street estimates, driven by strength in its pharmacy benefit unit and robust prescription volume at its retail pharmacies [1] Financial Performance - The company experienced a decrease in profit for the fourth quarter, yet managed to outperform analysts' expectations [1] - The performance was bolstered by the pharmacy benefit unit, indicating a strong demand for prescription services [1] Business Segments - The pharmacy benefit unit showed significant strength, contributing positively to the overall performance of CVS Health [1] - Retail pharmacies also reported strong prescription volume, which played a crucial role in the company's ability to beat estimates [1]

Financial Data and Key Metrics Changes - The Cigna Group reported revenues of $69.7 billion and adjusted earnings of $7.83 per share for the third quarter of 2025, reflecting sustained growth despite a dynamic market environment [6][33]. - The company recorded a net after-tax special item benefit of $61 million, equating to $0.23 per share [3]. Business Line Data and Key Metrics Changes - Evernorth Health Services achieved revenues of $60.4 billion, with pre-tax adjusted earnings of $1.9 billion, while specialty and care services revenues increased by 10% to $26.3 billion, and pre-tax adjusted earnings rose by 11% to $928 million [33][34]. - Cigna Healthcare reported third quarter revenues of $10.9 billion and pre-tax adjusted earnings of $1 billion, with a medical care ratio of 84.8% driven by an updated view of risk adjustment [35][36]. Market Data and Key Metrics Changes - The company noted that generic drugs account for 90% of all prescriptions in the U.S., with prices being one-third cheaper than in other countries, while brand name medications continue to rise significantly in cost [8][9]. - The median price for new FDA-approved drugs is projected to be approximately $390,000 for a treatment course in 2025, highlighting the affordability challenges in the market [9]. Company Strategy and Development Direction - The Cigna Group is focusing on a new rebate-free model for pharmacy benefits, aiming to improve healthcare affordability and streamline the patient experience [7][12]. - The company is strategically investing in expanding its addressable markets, including a recent investment in Shields Health Solutions to enhance specialty capabilities [6][19]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth despite challenges, reaffirming an adjusted EPS outlook of at least $29.60 for 2025 [16][33]. - The company anticipates margin pressure in the pharmacy benefit services segment due to strategic client renewals and investments in the new model, but expects long-term growth to remain strong [15][30]. Other Important Information - The company is committed to supporting independent pharmacists and ensuring fair pricing reimbursements, particularly in rural communities [14]. - Cigna Healthcare's growth is expected to be at the higher end of its long-term targets, with a focus on enhancing affordability and access to care [38]. Q&A Session Summary Question: Clarification on rebate guarantees and renewal pricing - Management clarified that the new rebate-free model is designed to be transparent and fee-based, aligning with regulatory priorities, and that the long-term growth algorithm for Evernorth remains intact despite short-term pressures [45][46]. Question: Magnitude of the 2026 decline in pharmacy benefit services - Management indicated that the decline in pharmacy benefit services income is expected to be driven by large client renewals and transitional investment spending, with specific figures not provided but a directional outline given [58][62]. Question: Adoption likelihood of the new model by employers - Management expressed confidence that the new model will be well-received by employers, emphasizing its benefits in terms of budget certainty and employee satisfaction [68][69]. Question: Profitability of large contracts - Management stated that while large contracts may have lower margin profiles, they do not operate at a loss and are strategically important for the company [73][76].

Financial Data and Key Metrics Changes - The company reported total revenue of $67.2 billion for the second quarter of 2025, with adjusted earnings per share increasing to $7.2, reflecting a sustained growth trajectory of 10% to 14% compounded adjusted EPS over the last decade [9][31][32] - Net after-tax special item charges amounted to $171 million, or $0.64 per share, impacting the overall financial results [5] Business Line Data and Key Metrics Changes - Cigna Healthcare's second quarter revenues were $10.8 billion, with pretax adjusted earnings of $1.1 billion and a medical care ratio of 83.2%, indicating stable performance despite elevated medical costs [33][34] - Evernorth's revenues grew to $57.8 billion, with pretax adjusted earnings reaching $1.7 billion, slightly exceeding expectations [32] - Specialty and Care Services within Evernorth saw a revenue increase of 13% to $25.9 billion, with adjusted earnings rising 12% year-over-year [32][24] Market Data and Key Metrics Changes - The specialty pharmacy market is projected to grow at high single digits annually, with Cigna Group expecting long-term average annual income growth of 8% to 11% across its specialty portfolio [26] - The individual exchange enrollment has increased nearly 50% over the past two years, although Cigna's customer base in this segment has decreased significantly due to a strategic focus on margin over growth [66] Company Strategy and Development Direction - The company aims to deliver innovative solutions to improve access and affordability in healthcare, focusing on a sustainable healthcare model [7][10] - Cigna Group emphasizes public-private partnerships to enhance responsiveness to stakeholder needs and has introduced an AI-powered virtual assistant to improve customer experience [12][13] - The company is strategically positioned with a diverse portfolio of businesses, allowing for multiple pathways for growth and adaptability in a dynamic market [14][15] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the dynamic operating environment, characterized by elevated regulatory activity and challenges in health status, affordability, and access [10][11] - The company reaffirms its guidance for full-year 2025 adjusted earnings per share of at least $29.6, indicating confidence in its operational execution and market positioning [31][35] Other Important Information - The company has strategically chosen not to engage in Medicaid or Medicare, opting instead to serve these customers through its Evernorth services portfolio [20] - Cigna Group's operating cash flow was impacted by working capital timing, but strong cash flow generation is anticipated in the second half of the year [36] Q&A Session Summary Question: Insights on innovative products and commercial market positioning - Management highlighted the growing significance of pharmacy services in the overall medical cost equation, noting that pharmacy services now represent mid-20s percentage of total costs, with expectations for further growth [41][42] Question: 2026 selling season and pharmacy benefit renewals - The company anticipates strong retention rates for its pharmacy benefit services and continues to focus on affordability and personalization in its offerings [50][52] Question: Update on individual exchange business and risk adjustment accruals - Management confirmed a strategic choice to prioritize margin over growth in the individual exchange market, resulting in a significant reduction in customer base but improved financial performance [66][68] Question: Impact of hospital billing and coding on commercial trends - Management acknowledged the sophistication in hospital billing and coding, noting that while it impacts the employer book, it does not have an outsized effect on the stop-loss portfolio [72][80] Question: Market dynamics and competitive pricing environment - The pricing environment is characterized as firm, with expectations for price increases in 2026 that exceed those achieved in 2025, reflecting ongoing elevated cost trends [93]